Fast, simultaneous quantification of three novel cardiac drugs in human urine by MEPS-UHPLC-MS/MS for therapeutic drug monitoring

被引:30
作者
Magiera, Sylwia [1 ]
机构
[1] Silesian Tech Univ, Dept Analyt Chem, PL-44100 Gliwice, Poland
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2013年 / 938卷
关键词
Drugs; Liquid chromatography; Mass spectrometry; Method validation; Microextraction by packed sorbent; RENIN INHIBITOR ALISKIREN; TANDEM MASS-SPECTROMETRY; FACTOR-XA INHIBITOR; HUMAN PLASMA; METABOLISM; PRASUGREL; RIVAROXABAN;
D O I
10.1016/j.jchromb.2013.09.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive and selective ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) method was developed for the fast, simultaneous quantification of three novel cardiac drugs (aliskiren, prasugrel and rivaroxaban) in human urine. Sample preparation was performed with microextraction with packed sorbent (MEPS), which is a miniaturization of solid phase extraction. The optimal conditions for MEPS extraction were obtained using C8 sorbent, small sample volumes and a short time period (about 3 min for the entire sample preparation step). Chromatographic separation of the selected compounds was achieved in less than 1.5 min on a Zorbax Rapid Resolution High Definition SB-C18 column using isocratic elution with 0.1% formic acid and acetonitrile (70:30, v/v) at a flow rate of 0.8 mL min(-1). The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring via an electrospray ionization source with positive ionization mode. The method was fully validated according to the latest recommendations of international guidelines. The lower limit of quantification was 5.0 pg mL(-1) for aliskiren and rivaroxaban and 0.5 pg mL(-1) for prasugrel. The intra- and inter-day precision was within 7.12% and the accuracy ranged from -7.54% to 4.17%. The mean extraction recoveries of the MEPSC8 methodology were found to be 98.3% for aliskiren, 100.3% for rivaroxaban and 99.9% for prasugrel. This MEPSC8-UHPLC-MS/MS method offers a fast, simple and precise way to determine selected novel cardiac drugs in human urine that could be applied to therapeutic drug monitoring and pharmacokinetic studies. (c) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:86 / 95
页数:10
相关论文
共 11 条
[1]  
[Anonymous], 1999, TDM8A NAT COMM CLIN, V19
[2]   Prasugrel in Clinical Practice. [J].
Bhatt, Deepak L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :940-942
[3]   Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry [J].
Farid, Nagy A. ;
McIntosh, Mary ;
Garofolo, Fabio ;
Wong, Ernest ;
Shwajch, Amanda ;
Kennedy, Monika ;
Young, Michelle ;
Sarkar, Pratibha ;
Kawabata, Kiyoshi ;
Takahashi, Makoto ;
Pang, Henrianna .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2007, 21 (02) :169-179
[4]  
Food and Drug Administration (USA), 2001, GUID IND AN PROC MET
[5]   In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans [J].
Lang, D. ;
Freudenberger, C. ;
Weinz, C. .
DRUG METABOLISM AND DISPOSITION, 2009, 37 (05) :1046-1055
[6]   Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure [J].
McMurray, John J. V. ;
Pitt, Bertram ;
Latini, Roberto ;
Maggioni, Aldo P. ;
Solomon, Scott D. ;
Keefe, Deborah L. ;
Ford, Jessica ;
Verma, Anil ;
Lewsey, Jim .
CIRCULATION-HEART FAILURE, 2008, 1 (01) :17-24
[7]   European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) [J].
Perk, Joep ;
De Backer, Guy ;
Gohlke, Helmut ;
Graham, Ian ;
Reiner, Zeljko ;
Verschuren, W. M. Monique ;
Albus, Christian ;
Benlian, Pascale ;
Boysen, Gudrun ;
Cifkova, Renata ;
Deaton, Christi ;
Ebrahim, Shah ;
Fisher, Miles ;
Germano, Giuseppe ;
Hobbs, Richard ;
Hoes, Arno ;
Karadeniz, Sehnaz ;
Mezzani, Alessandro ;
Prescott, Eva ;
Ryden, Lars ;
Scherer, Martin ;
Syvanne, Mikko ;
Reimer, Wilma J. M. Scholte Op ;
Vrints, Christiaan ;
Wood, David ;
Luis Zamorano, Jose ;
Zannad, Faiez .
EUROPEAN HEART JOURNAL, 2012, 33 (13) :1635-U130
[8]   Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry [J].
Rohde, G. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 872 (1-2) :43-50
[9]   Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers [J].
Waldmeier, Felix ;
Glaenzel, Ulrike ;
Wirz, Bernard ;
Oberer, Lukas ;
Schmid, Dietmar ;
Seiberling, Michael ;
Valencia, Jessica ;
Riviere, Gilles-Jacques ;
End, Peter ;
Vaidyanathan, Sujata .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (08) :1418-1428
[10]   New oral anticoagulants in development [J].
Weitz, Jeffrey I. .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (01) :62-70